The Anti-tumoral Efficacy of a Docetaxel-loaded Liposomal Drug Delivery System Modified with Transferrin for Ovarian Cancer

Abstract

To reduce the toxic effect on normal cells and improve the treatment effects of docetaxel, a novel transferrin modified docetaxel-loaded long circulating liposome for ovarian tumor was established for the first time. The transferrin-modified long-circulating liposomes loaded with docetaxel (TF-LP-DOC) were prepared by the post-insertion method and exhibited excellent characteristics in terms of particle size, encapsulation efficiency and stability. We investigated the targeting efficiencies of liposomes by the cellular uptake in vitro and biodistribution in vivo, and identified the therapeutic effects using cytotoxicity experiment (in vitro)and tumor growth inhibition (in vivo) on ovarian cancer. The in vitro and in vivo results showed that TF-LP-DOC were successfully established and presented an enhanced targeting ability. With decreased side effect and improved anti-tumor efficacy of chemotherapeutic drugs, TF-LP-DOC proved itself to be a very promising tumor targeted drug delivery system.

Key words

transferrin - long-circulating liposome - docetaxel - ovarian tumor

• References

• 1 Shahzad MM, Shin YH, Matsuo K et al. Biological significance of HORMA domain containing protein 1 (HORMAD1) in epithelial ovarian carcinoma. Cancer Lett 2013; 330: 123-129
• 2 Chao H, Wang L, Hao J et al. Low dosehistone deacetylase inhibitor, LBH589, potentiates anticancer effect of docetaxel in epithelial ovarian cancer via PI3K/Akt pathway. Cancer Lett 2013; 329: 17-26
• 3 Despierre E, Lambrechts D, Neven P et al. The molecular genetic basis of ovarian cancer and its roadmap towards a better treatment. Gynecol Oncol 2010; 117: 358-365
• 4 Gulbeyaz C, Adnan A, Ikbal C. Taxane-induced nail changes: Predictors and efficacy of the use of frozen gloves and socks in the prevention of nail toxicity. Eur J Oncol Nurs 2011; 16: 270-275
• 5 Manandhar S, Choi BH, Jung KA et al. NRF2 inhibition represses ErbB2 signaling in ovarian carcinoma cells: Implications for tumor growth retardation and sensitivity. Free Radical Bio Med 2012; 52: 1773-1785
• 6 Liang HF, Chen CT, Chen SC et al. Paclitaxel-loaded poly(γ-glutamic acid)-poly(lactide) nanoparticles as a targeted drug delivery system for the treatment of liver cancer. Biomaterials 2006; 27: 2051-2059
• 7 Ji Z, Lin G, Lu Q et al. Targeted therapy of SMMC-7721 liver cancer in vitro and in vivo with carbon nanotubes based drug delivery system. J Collid Interf Sci 2012; 365: 143-149
• 8 Silvia M. Challenges in design and characterization of ligand-targeted drug delivery systems. J Control Release 2012; 164: 125-137
• 9 Chiu SJ, Liu SJ, Perrotti D et al. Efficient delivery of a Bcl-2-specific antisense oligodeoxyribonucleotide (G3139) via transferrin receptor-targeted liposomes. J Controll Release 2006; 112: 199-207
• 10 Yang XJ, Koh CG, Liu SJ et al. Transferrin Receptor-Targeted Lipid Nanoparticles for Delivery of an Antisense Oligodeoxyribonucleotide against Bcl-2. Mol Pharm 2009; 6: 221-230
• 11 Chandran VI, Matesic L, Locke JM et al. Anti-cancer activity of an acid-labile N-alkylisatin conjugate targeting the transferrin receptor. Cancer Lett 2012; 316: 151-156
• 12 Oh S, Kim BJ, Singh NP et al. Synthesis and anti-cancer activity of covalent conjugates of artemisinin and a transferrin-receptor targeting peptide. Cancer Lett 2009; 274: 33-39
• 13 Ryo S, Tomoko T, Yasuhiro K et al. Effective anti-tumor activity of oxaliplatin encapsulated in transferrin–PEG-liposome. Int J Pharm 2008; 346: 143-150
• 14 Moganavelli S, Arthur H, Mario A. Lipoplexes with biotinylated transferrin accessories: Novel, targeted, serum-tolerant gene carriers. Int J Pharm 2006; 321: 124-137
• 15 Qu GW, Wu XL, Yin LF et al. N-octyl-O-sulfate chitosan-modified liposomes for delivery of docetaxel: Preparation, characterization, and pharmacokinetics. Biomed Pharmacother 2012; 66: 46-51
• 16 Iden DL, Allen TM. In vitro and in vivo comparison of I mmunoliposomes made by conventional coupling techniques with those made by a new post-insertion approach. Biochim Biophys Acta 2001; 1513: 207-216
• 17 João N, Moreira Tatsuhiro I. et al. Use of the Post-Insertion Technique to Insert Peptide Ligands into Pre-Formed Stealth Liposomes with Retention of Binding Activity and Cytotoxicity. Pharm Res 2002; 19: 265-269
• 18 Sang YH, Do YC, Hak KK et al. Preparation of Targeting Proteoliposome by Postinsertion of a Linker Molecule Conjugated with Recombinant Human Epidermal Growth Factor. Bioconjugate Chem 2010; 21: 345-351
• 19 Ishida T, Iden DL, Allen TM. A combinatorial approach to producing sterically stabilized (Stealth) immunoliposomal drugs. FEBS Lett 1990; 460: 129-133
• 20 Beuttler J, Rothdiener M, Mueller D et al. Targeting of epidermal growth factor receptor (EGFR)-expressing tumor cells with sterically stabilized affibody liposomes (SAL). Bioconjugate Chem 2009; 20: 1201-1208
• 21 Yang T, Cui FD, Choi MK et al. Enhanced solubility and stability of PEGylated liposomal paclitaxel: In vitro and in vivo evaluation. Int J Pharm 2007; 338: 317-326
• 22 Hiroto H, Hidetaka A, Kazuo M et al. Factors governing the in vivo tissue uptake of transferrin-coupled polyethylene glycol liposomes in vivo. Int J Pharm 2004; 281: 25-33
• 23 Kuai R, Yuan WM, Li WY et al. Targeted Delivery of Cargoes into a Murine Solid Tumor by a Cell-Penetrating Peptide and Cleavable Poly(ethylene glycol)Comodified Liposomal Delivery System via Systemic Administration. Mol Pharm 2011; 8: 2151-2161
• 24 Yang TY, Wang YG, Li ZQ et al. Targeted delivery of a combination therapy consisting of combretastatin A4 and lowdose doxorubicin against tumor neovasculature. 2012; 8: 81-92